CLINICAL APPLICATION OF ARGATROBAN AS AN ALTERNATIVE ANTICOAGULANT FOR EXTRACORPOREAL CIRCULATION

Anderson, 1990, Extracorporeal membrane oxygenation for pediatric cardiopulmonary failure, J Thorac Cardiovasc Surg, 99, 1011, 10.1016/S0022-5223(20)31457-4

Bauer, 1997, Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery, Circulation, 95, 1242, 10.1161/01.CIR.95.5.1242

Dietrich, 1991, The influence of preoperative anticoagulation on heparin response during cardiopulmonary bypass, J Thorac Cardiovasc Surg, 102, 505, 10.1016/S0022-5223(20)31420-3

Endo, 1997, Usefulness of argatroban, an antithrombin agent, in experimental short-term cardiopulmonary bypass using a membrane oxygenator and a centrifugal pump, Japanese Journal of Artificial Organs, 26, 641

Fenton, 1998, Thrombin and antithrombotics, Semin Thromb Hemost, 24, 87, 10.1055/s-2007-995828

Frenckner, 1992, Surface-heparinized neonatal ECMO circuit: An experimental animal study, Perfusion, 7, 47

Fukutake, 1991, Clinical pharmacology of argatroban, selective anti-thrombin agent: Comparative study with heparin, Cardioangiology (Japanese), 29, 190

Gravlee, 1990, Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation, J Thorac Cardiovasc Surg, 99, 518, 10.1016/S0022-5223(19)36983-1

Hara, 1986, Effect of argipidine (MD 805) on platelet function, Japanese Pharmacological Therapy, 14, 13

Hardart, 1999, Predictors of intracranial hemorrhage during neonatal extracorporeal membrane oxygenation, J Pediatr, 134, 156, 10.1016/S0022-3476(99)70408-7

Hermann, 1997, Clinical trials of direct thrombin inhibitors during invasive procedures, Thromb Haemost, 78, 367, 10.1055/s-0038-1657554

Horkay, 1992, Response to heparinization in adults and children undergoing cardiac operations, Ann Thorac Surg, 53, 822, 10.1016/0003-4975(92)91444-E

Kawada, 1992, Left heart bypass with the Bio-Meidicus centrifugal pump: The use of argatroban for preventing platelet loss, Artificial Organs Today, 2, 177

Kawada, 1999, Argatroban, an attractive anticoagulant, for left heart bypass with centrifugal pump for repair of traumatic aortic rupture, Journal of the Japanese Association for Thoracic Surgery, 47, 104

Lefkovits, 1994, Direct thrombin inhibitors in cardiovascular medicine, Circulation, 90, 1522, 10.1161/01.CIR.90.3.1522

Magovern, 1994, Extracorporeal membrane oxygenation: Preliminary results in patients with postcardiotomy cardiogenic shock, Ann Thorac Surg, 57, 1462, 10.1016/0003-4975(94)90101-5

Matsukura, 1983, Experimental extracorporeal circulation with a synthetic antithrombin agent, MD 805, without heparin, Journal of the Japanese Association for Thoracic Surgery, 31, 1377

Matsuo, 1987, Effect of a new synthetic anticoagulant (MD 805) on platelet, Japanese Journal of Hematology, 50, 654

Matsuo, 1997, Application of argatroban, direct thrombin inhibitor, in heparin-intolerant patients requiring extracorporeal circulation, Artif Organs, 21, 1035, 10.1111/j.1525-1594.1997.tb00519.x

Matsuwaka, 1990, Experimental evaluation of a heparin coated ECMO system simplified with a centrifugal pump, Transactions of the American Society For Artificial Internal Organs, 36, M473

Mitsui, 1999, Experience with emergency cardiac surgery following institution of percutaneous cardiopulmonary support, Artif Organs, 23, 496, 10.1046/j.1525-1594.1999.06389.x

Mooney, 1991, Emergency cardiopulmonary bypass support in patients with cardiac arrest, J Thorac Cardiovasc Surg, 101, 450, 10.1016/S0022-5223(19)36727-3

Mottaghy, 1989, Heparin free long-term extracorporeal circulation using bioactive surfaces, Transactions of the American Society For Artificial Internal Organs, 35, 635, 10.1097/00002480-198907000-00152

Okada, 1998, Use of an antithrombin agent, argatroban, in percutaneous cardiopulmonary support (PCPS) for patients undergoing cardiovascular surgery, Japanese Journal of Artificial Organs, 27, 394

Okada, 1999, Clinical application of argatroban as an anticoagulant for PCPS: Its advantages in reducing the risk of bleeding as determined by hemostatic molecular markers, Japanese Journal of Artificial Organs, 28, 412

Okamoto, 1981, Potent inhibition of thrombin by the newly synthesized arginine derivative, No 805: The importance of stereostructure of its hydrophobic carboxamide portion, Biochem Biophys Res Commun, 101, 440, 10.1016/0006-291X(81)91279-1

Ortel, 1998, New treatment options for heparin-induced thrombocytopenia, Semin Hematol, 35, 26

Phillips, 1983, Percutaneous initiation of cardiopulmonary bypass, Ann Thorac Surg, 36, 223, 10.1016/S0003-4975(10)60462-6

Phillips, 1989, Percutaneous cardiopulmonary bypass: Application and indication for use, Ann Thorac Surg, 47, 121, 10.1016/0003-4975(89)90252-X

Reichman, 1990, Improved patient survival after cardiac arrest using a cardiopulmonary support system, Ann Thorac Surg, 49, 101, 10.1016/0003-4975(90)90363-B

Sakai, 1999, Argatroban as a potential anticoagulant in cardiopulmonary bypass studies in a dog model, Cardiovasc Surg, 7, 187, 10.1016/S0967-2109(98)00119-7

Sasaki, 1999, Therapeutic strategy of perioperative use of percutaneous cardiopulmonary bypass support (PCPS) for adult cardiac surgery, Journal of the Japanese Association for Thoracic Surgery, 47, 20

Sinard, 1990, Extracorporeal membrane oxygenation (ECMO): Prolonged bedside cardiopulmonary bypass, Perfusion, 5, 239, 10.1177/026765919000500402

Swank, 1968, The screen filtration pressure method in platelet research. Significance and interpretation, Ser Hematol, 1, 146

Takano, 1993, Experimental study on heparin-free cardiopulmonary bypass using nafamostat mesilate (FUT-175) and heparin-coated circuit, Journal of the Japanese Association for Thoracic Surgery, 41, 2166

von Segesser, 1989, Cardiopulmonary bypass without systemic heparinization. Performance of heparin-coated oxygenators in comparison with classic membrane and bubble oxygenators, J Thorac Cardiovasc Surg, 98, 386, 10.1016/S0022-5223(19)34385-5

von Segesser, 1994, Risk and benefit of low systemic heparinization during open heart operations, Ann Thorac Surg, 58, 391, 10.1016/0003-4975(94)92213-6

Walenga, 1999, Coagulation laboratory testing in patients treated with argatroban, Semin Thromb Hemostas, 25, 61

Walenga, 1999, Glycosaminoglycans and the new antithrombotic drugs, Biomedical Progress, 12, 13

Walls, 1992, Heparin-induced thrombocytopenia in open heart surgical patients: Sequelae of late recognition, Ann Thorac Surg, 54, 787, 10.1016/0003-4975(92)91437-E

Weber, 1998, Extracorporeal membrane oxygenation for nonneonatal pulmonary and multiple-organ failure, J Pediatr Surg, 33, 1605, 10.1016/S0022-3468(98)90590-5

Young, 1978, Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer, Ann Thorac Surg, 26, 231, 10.1016/S0003-4975(10)63676-4